Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering
HAYWARD, Calif., Sept. 16, 2022 -- Benitec Biopharma Inc. , a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary... | September 16, 2022
United States San Francisco William Windham Exchange Commission Prospectus Department Benitec Biopharma Inc
Source: marketscreener.com